Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 513219, 10 pages
http://dx.doi.org/10.1155/2015/513219
Research Article

NT-proBNP as Early Marker of Subclinical Late Cardiotoxicity after Doxorubicin Therapy and Mediastinal Irradiation in Childhood Cancer Survivors

1Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt
2Pediatric Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt
3Pediatric Department, Faculty of Medicine, Cairo University, Cairo 11562, Egypt

Received 10 October 2014; Revised 25 January 2015; Accepted 23 February 2015

Academic Editor: Allan Jaffe

Copyright © 2015 Amal Zidan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. E. Gill, K. Savage, W. Z. Wysham, D. W. Blackhurst, W. E. Winter, and L. E. Puls, “Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?” Gynecologic Oncology, vol. 129, no. 3, pp. 544–547, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. L. C. M. Kremer, H. J. H. van der Pal, M. Offringa, E. C. van Dalen, and P. A. Voûte, “Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review,” Annals of Oncology, vol. 13, no. 6, pp. 819–829, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. H. J. Van Der Pal, E. C. Van Dalen, M. Hauptmann et al., “Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study,” Archives of Internal Medicine, vol. 170, no. 14, pp. 1247–1255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. L. C. M. Kremer, E. C. van Dalen, M. Offringa, and P. A. Voûte, “Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review,” Annals of Oncology, vol. 13, no. 4, pp. 503–512, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. S. E. Lipshultz, J. A. Alvarez, and R. E. Scully, “Anthracycline associated cardiotoxicity in survivors of childhood cancer,” Heart, vol. 94, no. 4, pp. 525–533, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Mladosievicova, D. Urbanova, E. Radvanska, P. Slavkovsky, and I. Simkova, “Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines,” Journal of Experimental & Clinical Cancer Research, vol. 31, no. 1, article 86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Horacek, M. Vasatova, M. Tichy, R. Pudil, L. Jebavy, and J. Maly, “The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia,” Experimental Oncology, vol. 32, no. 2, pp. 97–99, 2010. View at Google Scholar · View at Scopus
  8. M. I. Gharib and A. K. Burnett, “Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis,” European Journal of Heart Failure, vol. 4, no. 3, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Mukhopadhyay, S. Bátkai, M. Rajesh et al., “Pharmacological inhibition of CBI cannabinoid receptor protects against doxorubicin-induced cardiotoxicity,” Journal of the American College of Cardiology, vol. 50, no. 6, pp. 528–536, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Urbanova, L. Urban, I. Simkova, K. Danova, E. Mikuskova, and B. Mladosievicova, “Long-term cardiac effects of treatment for childhood leukemia,” Neoplasma, vol. 57, no. 2, pp. 179–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Kampmann, C. M. Wiethoff, A. Wenzel et al., “Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe,” Heart, vol. 83, no. 6, pp. 667–672, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. J. J. Lacuone, L. Steinherz, M. G. Oblenderet et al., “Modifications for toxicity,” in Supportive Care of Children with Cancer, A. R. Albin, Ed., pp. 79–109, The Johns Hopkins University Press, Baltimore, Md, USA, 2nd edition, 1997. View at Google Scholar
  13. L. Kapusta, J. M. Thijssen, M. H. M. Cuypers, P. G. M. Peer, and O. Daniëls, “Assessment of myocardial velocities in healthy children using tissue Doppler imaging,” Ultrasound in Medicine and Biology, vol. 26, no. 2, pp. 229–237, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Albers, T. S. Mir, M. Haddad, and S. Läer, “N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population,” Clinical Chemistry and Laboratory Medicine, vol. 44, no. 1, pp. 80–85, 2006. View at Google Scholar
  15. V. B. Pai and M. C. Nahata, “Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention,” Drug Safety, vol. 22, no. 4, pp. 263–302, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. K. K. Sundberg, C. Lampic, O. Björk, J. Arvidson, and L. Wettergren, “Positive and negative consequences of childhood cancer influencing the lives of young adults,” European Journal of Oncology Nursing, vol. 13, no. 3, pp. 164–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. M. Horacek, R. Pudil, L. Jebavy, M. Tichy, P. Zak, and J. Maly, “Assessment of anthracycline-induced cardiotoxicity with biochemical markers,” Experimental Oncology, vol. 29, no. 4, pp. 309–313, 2007. View at Google Scholar · View at Scopus
  18. A. M. C. Mavinkurve-Groothuis, J. Groot-Loonen, L. Bellersen et al., “Abnormal nt-pro-bnp levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines,” Pediatric Blood and Cancer, vol. 52, no. 5, pp. 631–636, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. L. M. Sherief, A. G. Kamal, E. A. Khalek, N. M. Kamal, A. A. A. Soliman, and A. M. Esh, “Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children,” Hematology, vol. 17, no. 3, pp. 151–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. J. Adams and S. E. Lipshultz, “Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention,” Pediatric Blood and Cancer, vol. 44, no. 7, pp. 600–606, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. B. D'Errico, L. Grimaldi, M. F. Petruzzelli et al., “NT-proBNP plasma levels as a potential biomarker for cardiac damage after radiotherapy in left-sided breast cancer patients,” International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 2, pp. 239–246, 2012. View at Google Scholar
  22. E. Braunwald, “Biomarkers in heart failure,” The New England Journal of Medicine, vol. 358, no. 20, pp. 2148–2159, 2008. View at Publisher · View at Google Scholar
  23. M. B. Diamond, V. I. Franco, T. L. Miller, and S. E. Lipshultz, “Preventing and treating anthracycline-related cardiotoxicity in survivors of childhood cancer,” Current Cancer Therapy Reviews, vol. 8, no. 2, pp. 141–151, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. B. M. P. Aleman, A. W. van den Belt-Dusebout, M. L. de Bruin et al., “Late cardiotoxicity after treatment for Hodgkin lymphoma,” Blood, vol. 109, no. 5, pp. 1878–1885, 2007. View at Google Scholar
  25. L. C. M. Kremer, E. C. van Dalen, M. Offringa, J. Ottenkamp, and P. A. Voûte, “Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study,” Journal of Clinical Oncology, vol. 19, no. 1, pp. 191–196, 2001. View at Google Scholar · View at Scopus
  26. T. Poutanen, T. Tikanoja, P. Riikonen, A. Silvast, and M. Perkkiö, “Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children,” Journal of Clinical Oncology, vol. 21, no. 12, pp. 2349–2356, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. S. E. Lipshultz, D. C. Landy, G. Lopez-Mitnik et al., “Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy,” Journal of Clinical Oncology, vol. 30, no. 10, pp. 1050–1057, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. F. A. Bu'Lock, M. G. Mott, A. Oakhill, and R. P. Martin, “Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology,” British Heart Journal, vol. 73, no. 4, pp. 340–350, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. S. E. Lipshultz, S. D. Colan, R. D. Gelber, A. R. Perez-Atayde, S. E. Sallan, and S. P. Sanders, “Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood,” The New England Journal of Medicine, vol. 324, no. 12, pp. 808–815, 1991. View at Publisher · View at Google Scholar · View at Scopus
  30. S. E. Lipshultz, S. R. Lipsitz, S. M. Mone et al., “Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer,” The New England Journal of Medicine, vol. 332, no. 26, pp. 1738–1743, 1995. View at Publisher · View at Google Scholar · View at Scopus
  31. S. E. Lipshultz, S. R. Lipsitz, S. E. Sallan et al., “Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2629–2636, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. A. S. Hinkle, C. Proukou, C. A. French et al., “A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses,” Pediatrics, vol. 113, no. 4, supplement, pp. 1141–1145, 2004. View at Google Scholar · View at Scopus
  33. S. M. Shankar, N. Marina, M. M. Hudson et al., “Monitoring for cardiovascular disease in survivors of childhood cancer: report from the cardiovascular disease task force of the children's oncology group,” Pediatrics, vol. 121, no. 2, pp. e387–e396, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. E. C. van Dalen, H. J. H. van der Pal, W. E. M. Kok, H. N. Caron, and L. C. M. Kremer, “Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study,” European Journal of Cancer, vol. 42, no. 18, pp. 3191–3198, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Barry, J. A. Alvarez, R. E. Scully, T. L. Miller, and S. E. Lipshultz, “Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management,” Expert Opinion on Pharmacotherapy, vol. 8, no. 8, pp. 1039–1058, 2007. View at Google Scholar · View at Scopus
  36. L. Gianni, E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan, and D. B. Sawyer, “Anthracycline cardiotoxicity: from bench to bedside,” Journal of Clinical Oncology, vol. 26, no. 22, pp. 3777–3784, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. D.-R. Pu, J. R. Chiong, and Q.-C. Zhou, “Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases,” Heart Failure Reviews, vol. 15, no. 4, pp. 293–304, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Fried, B. Bar-Oz, Z. Perles, A. J. J. T. Rein, Z. Zonis, and A. Nir, “N-terminal pro-B-type natriuretic peptide levels in acute versus chronic left ventricular dysfunction,” Journal of Pediatrics, vol. 149, no. 1, pp. 28–31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Nasser, Z. Perles, A. J. J. T. Rein, and A. Nir, “NT-proBNP as a marker for persistent cardiac disease in children with history of dilated cardiomyopathy and myocarditis,” Pediatric Cardiology, vol. 27, no. 1, pp. 87–90, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Soker and M. Kervancioglu, “Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy,” Saudi Medical Journal, vol. 26, no. 8, pp. 1197–1202, 2005. View at Google Scholar · View at Scopus
  41. I. Germanakis, M. Kalmanti, F. Parthenakis et al., “Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines,” International Journal of Cardiology, vol. 108, no. 2, pp. 212–215, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. W. Hongkan, J. Soongswang, G. Veerakul et al., “N-terminal pro brain natriuretic peptide and cardiac function in doxorubicin administered pediatric patients,” Journal of the Medical Association of Thailand, vol. 92, no. 11, pp. 1450–1457, 2009. View at Google Scholar · View at Scopus
  43. Y. Pongprot, R. Sittiwangkul, P. Charoenkwan, and S. Silvilairat, “Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer,” Journal of Pediatric Hematology/Oncology, vol. 34, no. 8, pp. 589–595, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. C. A. J. Brouwer, A. Postma, J. M. Vonk et al., “Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer,” European Journal of Cancer, vol. 47, no. 16, pp. 2453–2462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. I. Dorup, G. Levitt, I. Sullivan, and K. Sorensen, “Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function,” Heart, vol. 90, no. 10, pp. 1214–1216, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Takenaka, Y. Kuwada, M. Sonoda et al., “Anthracycline-induced cardiomyopathies evaluated by tissue Doppler tracking system and strain rate imaging,” Journal of Cardiology, vol. 37, no. 1, pp. 129–132, 2001. View at Google Scholar · View at Scopus
  47. L. Kapusta, J. M. Thijssen, J. Groot-Loonen, T. Antonius, J. Mulder, and O. Daniëls, “Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines,” Ultrasound in Medicine and Biology, vol. 26, no. 7, pp. 1099–1108, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Rathe, N. L. T. Carlsen, and H. Oxhøj, “Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia,” Pediatric Blood & Cancer, vol. 48, no. 7, pp. 663–667, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Yildirim, F. S. Tunaoglu, K. Kambur, and F. G. Pinarli, “The utility of NTproBNP and various echocardiographic methods in the determination of doxorubicin induced subclinical late cardiotoxicity,” Kardiologia Polska, vol. 71, no. 1, pp. 40–46, 2013. View at Google Scholar · View at Scopus
  50. C.-M. Yu, J. E. Sanderson, T. H. Marwick, and J. K. Oh, “Tissue Doppler imaging a new prognosticator for cardiovascular diseases,” Journal of the American College of Cardiology, vol. 49, no. 19, pp. 1903–1914, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. C. M. Yu, J. W. Fung, Q. Zhang et al., “Tissue Doppler echocardiographic evidence of atrial mechanical dysfunction in coronary artery disease,” International Journal of Cardiology, vol. 105, no. 2, pp. 178–185, 2005. View at Publisher · View at Google Scholar